Pacer Advisors
MYGN icon

Pacer Advisors’s Myriad Genetics MYGN Stock Holding History

Pacer Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8K Buy
+1,400
New +$6.36K ﹤0.01% 2368
2024
Q3 		– Sell
-532
Closed -$13K – 2642
2024
Q2 		$13K Sell
532
-628
-54% -$13.8K ﹤0.01% 3510
2024
Q1 		$24.7K Buy
+1,160
New +$24.9K ﹤0.01% 3402
2021
Q2 		– Sell
-2,510
Closed -$76K – 1496
2021
Q1 		$76K Sell
2,510
-396
-14% -$11.2K ﹤0.01% 1338
2020
Q4 		$57K Sell
2,906
-2,936
-50% -$47.4K ﹤0.01% 1405
2020
Q3 		$76K Buy
+5,842
New +$73.9K ﹤0.01% 1283
2018
Q4 		– Sell
-5,140
Closed -$236K – 864
2018
Q3 		$236K Buy
+5,140
New +$229K 0.01% 997
2018
Q2 		– Sell
-1,588
Closed -$47K – 1185
2018
Q1 		$47K Sell
1,588
-462
-23% -$15.6K ﹤0.01% 970
2017
Q4 		$70K Buy
+2,050
New +$69.2K ﹤0.01% 987
2017
Q3 		– Sell
-1,390
Closed -$36K – 1234
2017
Q2 		$36K Buy
+1,390
New +$29.5K ﹤0.01% 1136

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pacer Advisors's MYGN Position: Q2 2026 in Review

Pacer Advisors opened a new position in Myriad Genetics (MYGN) in Q2 2026: 1,400 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #2368 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in MYGN as recently as Q2 2024.

Pacer Advisors first reported a position in MYGN in Q2 2017 and has held it in 10 quarters since. The position peaked at $236K in Q3 2018. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Pacer Advisors held 1,400 shares of Myriad Genetics worth $8K as of Q2 2026.
  • Myriad Genetics was a new Pacer Advisors position in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2368 holding.
  • Pacer Advisors first reported a position in Myriad Genetics in Q2 2017 and has held it in 10 quarters since.
  • Pacer Advisors's Myriad Genetics position peaked at $236K in Q3 2018.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.